Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
Year: 2013
Type: article
Abstract: Type 2 diabetes mellitus (T2DM) is aserious, chronic, and progressivedisease that is rapidly increasing in prevalence. The disease now affects.10 % of adults in some developed coun-tries, increasing most in Asia. People with T2DM are two to four times more likely to develop a serious cardiovascular (CV) outcome compared with those without diabetes. The majority of patients with T2DM are insulin resistant and have asso-ciated metabolic abnormalities that are themselves significant CV risk factors. It is believed that most of this increased risk is caused by lipid abnormalities, hyper-tension, chronic vascular inflammation, and a proatherothrombotic state. The glycemia-related contribution is evidently
Source: Diabetes Care
DOI: 10.2337/dcs13-2031
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2119214646
